Hosted on MSN12mon
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor ConfidenceThe setback of OCEANIC-AF is likely to diminish investor confidence in Factor XIa inhibitors' capability to outperform Eliquis in atrial fibrillation, impacting ongoing trials such as the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback